BMY
Bristol-Myers Squibb Company
Price Chart
Latest Quote
$57.27
+0.67 (+1.18%)
Current Price
| Previous Close | $56.60 |
| Open | $57.03 |
| Day High | $57.81 |
| Day Low | $56.79 |
| Volume | 9,516,350 |
Stock Information
| Quarterly Dividend / Yield | $2.52 / 4.45% |
| Shares Outstanding | 2.04B |
| Quarterly Dividend Yield | 4.45% |
| Quarterly Dividend | $2.52 |
| Total Debt | $46.43B |
| Cash Equivalents | $10.49B |
| Revenue | $48.48B |
| Net Income | $7.27B |
| Sector | Healthcare |
| Industry | Drug Manufacturers - General |
| Market Cap | $116.95B |
| P/E Ratio | 16.04 |
| EPS (TTM) | $3.57 |
| Exchange | NYQ |
đ Comprehensive Analysis
Company Data
| Enterprise Value | $151.56B |
| Sales | $48.48B |
| Income | $7.27B |
| Book/sh | $9.83 |
| Cash/sh | $5.13 |
| Employees | 32K |
Financial Ratios
| Quick Ratio | 1.18 |
| Current Ratio | 1.42 |
| Debt/Eq | 230.97 |
| EPS Growth TTM | 9.00% |
Returns & Margins
| ROA | 10.69% |
| ROE | 38.73% |
| Gross Margin | 71.98% |
| Operating Margin | 33.04% |
| Profit Margin | 15.01% |
Ownership
| Insider Ownership | 0.08% |
| Institutional Ownership | 83.80% |
| Insider & Institutional transactions data not available | |
Valuation Ratios
| Forward P/E | 9.29 |
| PEG | 173.44 |
| P/S | 2.41 |
| P/B | 5.83 |
Analyst Data
| Recommendation | hold |
| Target Price | $63.08 |
Technical Indicators
| SMA20 | $56.96 |
| SMA50 | $57.96 |
| SMA200 | $52.45 |
| RSI | 51.23 |
| ATR | 1.4832 |
| Shares Float | 2.04B |
| Short Float | 1.80% |
| Short Ratio | 3.65 |
| Volatility | 0.24 |
| Rel Volume | 0.86 |
Performance History
| Week | +0.16% |
| Month | +1.20% |
| Quarter | -4.03% |
| 6 Months | +14.88% |
| YTD | +8.23% |
| Year | +25.40% |
| 3 Years | +2.10% |
| 5 Years | +6.53% |
| 10 Years | +9.00% |
Stock Score:
â Premium
Based on debt, profitability, growth, and cash flow metrics
â Premium Feature
Sign up for free to view detailed scoring breakdown â premium is free during our trial period!
Recent Price History
| Date | Close | Volume |
|---|---|---|
| 2026-06-05 | $57.27 | 9,516,350 |
| 2026-06-04 | $56.60 | 12,659,100 |
| 2026-06-03 | $54.72 | 11,540,700 |
| 2026-06-02 | $54.46 | 13,739,900 |
| 2026-06-01 | $54.95 | 20,579,800 |
| 2026-05-29 | $57.18 | 27,566,000 |
| 2026-05-28 | $56.91 | 12,074,800 |
| 2026-05-27 | $57.52 | 9,347,600 |
| 2026-05-26 | $58.03 | 8,159,500 |
| 2026-05-22 | $59.46 | 6,489,200 |
| 2026-05-21 | $59.55 | 8,451,100 |
| 2026-05-20 | $58.54 | 8,547,200 |
| 2026-05-19 | $58.31 | 7,998,900 |
| 2026-05-18 | $57.31 | 11,659,300 |
| 2026-05-15 | $57.00 | 10,824,000 |
| 2026-05-14 | $56.77 | 7,687,000 |
| 2026-05-13 | $56.39 | 7,997,500 |
| 2026-05-12 | $56.45 | 9,274,000 |
| 2026-05-11 | $55.67 | 8,390,900 |
| 2026-05-08 | $56.16 | 10,033,000 |
| 2026-05-07 | $56.25 | 10,419,800 |
| 2026-05-06 | $56.59 | 10,439,400 |
About Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for oncology, hematology, immunology, cardiovascular, neuroscience, and other areas. The company's products include Opdivo for various anti-cancer indications; Opdivo Qvantig, a subcutaneous PD-1 inhibitor for solid tumorsr; Orencia for active rheumatoid arthritis and psoriatic arthritis; Yervoy for the treatment of patients with unresectable or metastatic melanoma; Reblozyl to treat anemia; Breyanzi for the treatment of patients with relapsed or refractory large B-cell lymphoma; Opdualag for the treatment of unresectable or metastatic melanoma; and Camzyos to treat symptomatic obstructive HCM to improve functional capacity and symptom. It also offers Zeposia to treat relapsing forms of multiple sclerosis; Abecma for the treatment of patients with relapsed or refractory multiple myeloma; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Krazati for the treatment of adult patients with KRASG12C-mutated locally advanced or metastatic non-small cell lung cancer (NSCLC); and Cobenfy to treat schizophrenia. In addition, it offers Eliquis for a reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation and for the treatment of DVT/PE; Revlimid, an oral immunomodulatory drug to treat multiple myeloma; Pomalyst/Imnovid for multiple myeloma; Sprycel for Philadelphia chromosome-positive chronic myeloid leukemia; and Abraxane for the treatment of breast cancer. Further, it provides Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; and NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, specialty pharmacies, and to a lesser extent, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. The company was founded in 1887 and is headquartered in Princeton, New Jersey.
đ° Latest News
Billionaire Izzy Englander Just Made a Big Bet on This Beaten-Down High-Yield Dividend Stock
Motley Fool âĸ 2026-06-05T18:20:00Z
AGEN Early Access Revenues Signal a New Path Ahead of Approval
Zacks âĸ 2026-06-05T18:01:00Z
Is Agenus Stock a Hold Amid Valuation and Funding Risks?
Zacks âĸ 2026-06-05T17:59:00Z
AGEN BOT+BAL: What the BATTMAN Trial Means for mCRC
Zacks âĸ 2026-06-05T17:54:00Z
How Investors May Respond To Bristol Myers Squibb (BMY) Winning EU Nod For First-Line Opdivo Regimen
Simply Wall St. âĸ 2026-06-05T04:39:34Z
3 Value Stocks We Think Twice About
StockStory âĸ 2026-06-04T20:13:30Z
REGN Expands Cancer Deal With CytomX for Bispecific Therapeutics
Zacks âĸ 2026-06-04T17:25:00Z
Arcus, Bristol Myers Team Up to Advance Kidney Cancer Study
Zacks âĸ 2026-06-04T15:53:00Z
Bristol-Myers Squibb Cancer Wins Test Investor Patience On Valuation
Simply Wall St. âĸ 2026-06-04T10:11:26Z
Better High-Yield Dividend Stock to Buy: Bristol Myers Squibb or Pfizer?
Motley Fool âĸ 2026-06-04T06:50:00Z
Period:
Loading...
Income Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Revenue | ||||
| Reconciled Cost Of Revenue | $13,242,000,000 | $13,240,000,000 | $9,980,000,000 | $9,456,000,000 |
| Cost Of Revenue | $13,936,000,000 | $13,968,000,000 | $10,693,000,000 | $10,137,000,000 |
| Total Revenue | $48,195,000,000 | $48,300,000,000 | $45,006,000,000 | $46,159,000,000 |
| Operating Revenue | $47,203,000,000 | $47,257,000,000 | $44,386,000,000 | $45,413,000,000 |
| Expenses | ||||
| Interest Expense | $1,891,000,000 | $1,947,000,000 | $1,166,000,000 | $1,232,000,000 |
| Total Expenses | $34,471,000,000 | $42,413,000,000 | $36,811,000,000 | $37,055,000,000 |
| Other Income Expense | $-2,504,000,000 | $-12,319,000,000 | $1,411,000,000 | $-159,000,000 |
| Other Non Operating Income Expenses | $2,211,000,000 | $1,613,000,000 | $2,284,000,000 | $2,034,000,000 |
| Net Non Operating Interest Income Expense | $-1,891,000,000 | $-1,947,000,000 | $-1,166,000,000 | $-1,232,000,000 |
| Interest Expense Non Operating | $1,891,000,000 | $1,947,000,000 | $1,166,000,000 | $1,232,000,000 |
| Operating Expense | $20,535,000,000 | $28,445,000,000 | $26,118,000,000 | $26,918,000,000 |
| Selling And Marketing Expense | - | - | - | $7,814,000,000 |
| General And Administrative Expense | - | - | - | $7,814,000,000 |
| Income & Earnings | ||||
| Net Income From Continuing Operation Net Minority Interest | $7,054,000,000 | $-8,948,000,000 | $8,025,000,000 | $6,327,000,000 |
| Net Interest Income | $-1,891,000,000 | $-1,947,000,000 | $-1,166,000,000 | $-1,232,000,000 |
| Normalized Income | $10,620,578,045 | $2,058,280,000 | $8,856,969,000 | $8,131,839,000 |
| Net Income From Continuing And Discontinued Operation | $7,054,000,000 | $-8,948,000,000 | $8,025,000,000 | $6,327,000,000 |
| Net Income Common Stockholders | $7,054,000,000 | $-8,948,000,000 | $8,025,000,000 | $6,327,000,000 |
| Net Income | $7,054,000,000 | $-8,948,000,000 | $8,025,000,000 | $6,327,000,000 |
| Net Income Including Noncontrolling Interests | $7,055,000,000 | $-8,933,000,000 | $8,040,000,000 | $6,345,000,000 |
| Net Income Continuous Operations | $7,055,000,000 | $-8,933,000,000 | $8,040,000,000 | $6,345,000,000 |
| Pretax Income | $9,328,000,000 | $-8,379,000,000 | $8,440,000,000 | $7,713,000,000 |
| Special Income Charges | $-5,225,000,000 | $-14,426,000,000 | $-1,162,000,000 | $-1,563,000,000 |
| Operating Income | $13,724,000,000 | $5,887,000,000 | $8,195,000,000 | $9,104,000,000 |
| Depreciation Amortization Depletion Income Statement | $3,317,000,000 | $8,872,000,000 | $9,047,000,000 | $9,595,000,000 |
| Depreciation And Amortization In Income Statement | $3,317,000,000 | $8,872,000,000 | $9,047,000,000 | $9,595,000,000 |
| Amortization Of Intangibles Income Statement | $3,317,000,000 | $8,872,000,000 | $9,047,000,000 | $9,595,000,000 |
| Gross Profit | $34,259,000,000 | $34,332,000,000 | $34,313,000,000 | $36,022,000,000 |
| Earnings From Equity Interest | - | - | $-160,000,000 | $-801,000,000 |
| Per Share | ||||
| Diluted EPS | $3.46 | $-4.41 | $3.86 | $2.95 |
| Basic EPS | $3.47 | $-4.41 | $3.88 | $2.97 |
| Other | ||||
| Tax Effect Of Unusual Items | $-1,148,421,955 | $-2,925,720,000 | $-41,031,000 | $-388,161,000 |
| Tax Rate For Calcs | $0 | $0 | $0 | $0 |
| Normalized EBITDA (Bullshit earnings) | $19,945,000,000 | $17,100,000,000 | $20,239,000,000 | $21,414,000,000 |
| Total Unusual Items | $-4,715,000,000 | $-13,932,000,000 | $-873,000,000 | $-2,193,000,000 |
| Total Unusual Items Excluding Goodwill | $-4,715,000,000 | $-13,932,000,000 | $-873,000,000 | $-2,193,000,000 |
| Reconciled Depreciation | $4,011,000,000 | $9,600,000,000 | $9,760,000,000 | $10,276,000,000 |
| EBITDA (Bullshit earnings) | $15,230,000,000 | $3,168,000,000 | $19,366,000,000 | $19,221,000,000 |
| EBIT | $11,219,000,000 | $-6,432,000,000 | $9,606,000,000 | $8,945,000,000 |
| Diluted Average Shares | $2,039,000,000 | $2,027,000,000 | $2,078,000,000 | $2,146,000,000 |
| Basic Average Shares | $2,034,000,000 | $2,027,000,000 | $2,069,000,000 | $2,130,000,000 |
| Diluted NI Availto Com Stockholders | $7,054,000,000 | $-8,948,000,000 | $8,025,000,000 | $6,327,000,000 |
| Minority Interests | $-2,000,000 | $-15,000,000 | $-15,000,000 | $-18,000,000 |
| Tax Provision | $2,272,000,000 | $554,000,000 | $400,000,000 | $1,368,000,000 |
| Other Special Charges | $434,000,000 | $84,000,000 | $-390,000,000 | $444,000,000 |
| Restructuring And Mergern Acquisition | $4,791,000,000 | $14,342,000,000 | $1,552,000,000 | $1,330,000,000 |
| Gain On Sale Of Security | $510,000,000 | $494,000,000 | $289,000,000 | $-630,000,000 |
| Amortization | $3,317,000,000 | $8,872,000,000 | $9,047,000,000 | $9,595,000,000 |
| Research And Development | $9,951,000,000 | $11,159,000,000 | $9,299,000,000 | $9,509,000,000 |
| Selling General And Administration | $7,267,000,000 | $8,414,000,000 | $7,772,000,000 | $7,814,000,000 |
| Gain On Sale Of Business | - | $-15,000,000 | $0 | $211,000,000 |
| Impairment Of Capital Assets | - | $47,000,000 | $29,000,000 | $0 |
| Other Gand A | - | - | - | $7,814,000,000 |
| Other Taxes | - | - | - | - |
| Salaries And Wages | - | - | - | - |
Fetched: 2026-05-23
Balance Sheet (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Assets | ||||
| Net Tangible Assets | $-22,634,000,000 | $-29,027,000,000 | $-19,224,000,000 | $-26,443,000,000 |
| Total Assets | $90,038,000,000 | $92,603,000,000 | $95,159,000,000 | $96,820,000,000 |
| Total Non Current Assets | $60,648,000,000 | $62,823,000,000 | $63,389,000,000 | $69,547,000,000 |
| Other Non Current Assets | $2,201,000,000 | $2,123,000,000 | $1,148,000,000 | $752,000,000 |
| Non Current Deferred Assets | $5,378,000,000 | $4,236,000,000 | $2,768,000,000 | $1,344,000,000 |
| Non Current Deferred Taxes Assets | $5,378,000,000 | $4,236,000,000 | $2,768,000,000 | $1,344,000,000 |
| Investmentin Financial Assets | $411,000,000 | $772,000,000 | $800,000,000 | $0 |
| Goodwill And Other Intangible Assets | $41,107,000,000 | $45,362,000,000 | $48,654,000,000 | $57,504,000,000 |
| Other Intangible Assets | $19,353,000,000 | $23,643,000,000 | $27,485,000,000 | $36,355,000,000 |
| Current Assets | $29,390,000,000 | $29,780,000,000 | $31,770,000,000 | $27,273,000,000 |
| Other Current Assets | $1,502,000,000 | $1,940,000,000 | $1,509,000,000 | $1,596,000,000 |
| Inventory | $2,690,000,000 | $2,557,000,000 | $2,662,000,000 | $2,339,000,000 |
| Receivables | $14,525,000,000 | $14,424,000,000 | $15,264,000,000 | $13,937,000,000 |
| Other Receivables | $2,013,000,000 | $2,120,000,000 | $2,455,000,000 | $2,239,000,000 |
| Taxes Receivable | $2,920,000,000 | $3,292,000,000 | $3,927,000,000 | $3,547,000,000 |
| Accounts Receivable | $9,592,000,000 | $9,012,000,000 | $8,882,000,000 | $8,151,000,000 |
| Allowance For Doubtful Accounts Receivable | $-1,778,000,000 | $-945,000,000 | $-669,000,000 | $-697,000,000 |
| Gross Accounts Receivable | $11,370,000,000 | $9,957,000,000 | $9,551,000,000 | $8,848,000,000 |
| Cash Cash Equivalents And Short Term Investments | $10,673,000,000 | $10,859,000,000 | $12,280,000,000 | $9,253,000,000 |
| Cash And Cash Equivalents | $10,209,000,000 | $10,346,000,000 | $11,464,000,000 | $9,123,000,000 |
| Restricted Cash | - | $0 | $55,000,000 | $148,000,000 |
| Non Current Accounts Receivable | - | - | $436,000,000 | - |
| Debt | ||||
| Net Debt | $34,902,000,000 | $39,303,000,000 | $28,308,000,000 | $30,197,000,000 |
| Total Debt | $47,139,000,000 | $51,200,000,000 | $41,464,000,000 | $40,717,000,000 |
| Long Term Debt And Capital Lease Obligation | $44,676,000,000 | $48,973,000,000 | $38,183,000,000 | $36,317,000,000 |
| Long Term Debt | $42,850,000,000 | $47,603,000,000 | $36,653,000,000 | $35,056,000,000 |
| Current Debt And Capital Lease Obligation | $2,463,000,000 | $2,227,000,000 | $3,281,000,000 | $4,400,000,000 |
| Current Debt | $2,261,000,000 | $2,046,000,000 | $3,119,000,000 | $4,264,000,000 |
| Other Current Borrowings | $2,261,000,000 | $2,046,000,000 | $3,119,000,000 | $4,264,000,000 |
| Liabilities | ||||
| Minimum Pension Liabilities | $-566,000,000 | $-648,000,000 | $-738,000,000 | $-623,000,000 |
| Total Liabilities Net Minority Interest | $71,532,000,000 | $76,215,000,000 | $65,674,000,000 | $65,702,000,000 |
| Total Non Current Liabilities Net Minority Interest | $48,115,000,000 | $52,441,000,000 | $43,412,000,000 | $43,812,000,000 |
| Other Non Current Liabilities | $824,000,000 | $522,000,000 | $396,000,000 | $303,000,000 |
| Tradeand Other Payables Non Current | $1,407,000,000 | $1,491,000,000 | $3,288,000,000 | $3,992,000,000 |
| Non Current Deferred Liabilities | $878,000,000 | $1,055,000,000 | $1,065,000,000 | $2,798,000,000 |
| Non Current Deferred Taxes Liabilities | $222,000,000 | $369,000,000 | $338,000,000 | $2,166,000,000 |
| Current Liabilities | $23,417,000,000 | $23,774,000,000 | $22,262,000,000 | $21,890,000,000 |
| Other Current Liabilities | $13,072,000,000 | $12,907,000,000 | $11,498,000,000 | $10,566,000,000 |
| Payables And Accrued Expenses | $6,321,000,000 | $6,946,000,000 | $6,192,000,000 | $5,499,000,000 |
| Interest Payable | $484,000,000 | $572,000,000 | $349,000,000 | $321,000,000 |
| Payables | $5,837,000,000 | $6,374,000,000 | $5,843,000,000 | $5,178,000,000 |
| Dividends Payable | $1,283,000,000 | $1,258,000,000 | $1,213,000,000 | $1,196,000,000 |
| Total Tax Payable | $979,000,000 | $1,514,000,000 | $1,371,000,000 | $942,000,000 |
| Income Tax Payable | $979,000,000 | $1,514,000,000 | $1,371,000,000 | $942,000,000 |
| Accounts Payable | $3,575,000,000 | $3,602,000,000 | $3,259,000,000 | $3,040,000,000 |
| Equity | ||||
| Common Stock Equity | $18,473,000,000 | $16,335,000,000 | $29,430,000,000 | $31,061,000,000 |
| Total Equity Gross Minority Interest | $18,506,000,000 | $16,388,000,000 | $29,485,000,000 | $31,118,000,000 |
| Stockholders Equity | $18,473,000,000 | $16,335,000,000 | $29,430,000,000 | $31,061,000,000 |
| Gains Losses Not Affecting Retained Earnings | $-1,523,000,000 | $-1,238,000,000 | $-1,546,000,000 | $-1,281,000,000 |
| Other Equity Adjustments | $40,000,000 | $378,000,000 | $4,000,000 | $232,000,000 |
| Retained Earnings | $16,896,000,000 | $14,912,000,000 | $28,766,000,000 | $25,503,000,000 |
| Long Term Equity Investment | $2,096,000,000 | $1,736,000,000 | $1,699,000,000 | $2,187,000,000 |
| Other | ||||
| Treasury Shares Number | $887,000,000 | $894,000,000 | $902,000,000 | $825,000,000 |
| Preferred Shares Number | $3,484 | $3,484 | $3,484 | $3,484 |
| Ordinary Shares Number | $2,035,753,027 | $2,029,000,000 | $2,021,000,000 | $2,075,000,000 |
| Share Issued | $2,922,753,027 | $2,923,000,000 | $2,923,000,000 | $2,900,000,000 |
| Tangible Book Value | $-22,634,000,000 | $-29,027,000,000 | $-19,224,000,000 | $-26,443,000,000 |
| Invested Capital | $63,584,000,000 | $65,984,000,000 | $69,202,000,000 | $70,381,000,000 |
| Working Capital | $5,973,000,000 | $6,006,000,000 | $9,508,000,000 | $5,383,000,000 |
| Capital Lease Obligations | $2,028,000,000 | $1,551,000,000 | $1,692,000,000 | $1,397,000,000 |
| Total Capitalization | $61,323,000,000 | $63,938,000,000 | $66,083,000,000 | $66,117,000,000 |
| Minority Interest | $33,000,000 | $53,000,000 | $55,000,000 | $57,000,000 |
| Foreign Currency Translation Adjustments | $-997,000,000 | $-968,000,000 | $-812,000,000 | $-890,000,000 |
| Treasury Stock | $43,579,000,000 | $43,655,000,000 | $43,766,000,000 | $38,618,000,000 |
| Additional Paid In Capital | $46,387,000,000 | $46,024,000,000 | $45,684,000,000 | $45,165,000,000 |
| Capital Stock | $292,000,000 | $292,000,000 | $292,000,000 | $292,000,000 |
| Common Stock | $292,000,000 | $292,000,000 | $292,000,000 | $292,000,000 |
| Preferred Stock | $0 | $0 | $0 | $0 |
| Employee Benefits | $330,000,000 | $400,000,000 | $480,000,000 | $402,000,000 |
| Non Current Pension And Other Postretirement Benefit Plans | $330,000,000 | $400,000,000 | $480,000,000 | $402,000,000 |
| Non Current Deferred Revenue | $169,000,000 | $230,000,000 | $300,000,000 | $283,000,000 |
| Long Term Capital Lease Obligation | $1,826,000,000 | $1,370,000,000 | $1,530,000,000 | $1,261,000,000 |
| Current Capital Lease Obligation | $202,000,000 | $181,000,000 | $162,000,000 | $136,000,000 |
| Pensionand Other Post Retirement Benefit Plans Current | $1,561,000,000 | $1,694,000,000 | $1,291,000,000 | $1,425,000,000 |
| Current Accrued Expenses | $484,000,000 | $572,000,000 | $349,000,000 | $321,000,000 |
| Defined Pension Benefit | $330,000,000 | $234,000,000 | $284,000,000 | $285,000,000 |
| Investments And Advances | $2,507,000,000 | $2,508,000,000 | $2,499,000,000 | $2,187,000,000 |
| Held To Maturity Securities | $15,000,000 | $452,000,000 | $436,000,000 | $0 |
| Available For Sale Securities | $396,000,000 | $320,000,000 | $364,000,000 | - |
| Goodwill | $21,754,000,000 | $21,719,000,000 | $21,169,000,000 | $21,149,000,000 |
| Net PPE | $9,125,000,000 | $8,360,000,000 | $8,036,000,000 | $7,475,000,000 |
| Accumulated Depreciation | $-5,293,000,000 | $-4,949,000,000 | $-4,803,000,000 | $-4,164,000,000 |
| Gross PPE | $14,418,000,000 | $13,309,000,000 | $12,839,000,000 | $11,639,000,000 |
| Construction In Progress | $1,619,000,000 | $1,525,000,000 | $1,075,000,000 | $1,053,000,000 |
| Other Properties | $1,582,000,000 | $1,224,000,000 | $1,390,000,000 | $1,220,000,000 |
| Machinery Furniture Equipment | $3,790,000,000 | $3,818,000,000 | $3,717,000,000 | $3,284,000,000 |
| Buildings And Improvements | $7,270,000,000 | $6,581,000,000 | $6,495,000,000 | $5,920,000,000 |
| Land And Improvements | $157,000,000 | $161,000,000 | $162,000,000 | $162,000,000 |
| Properties | $0 | $0 | $0 | $0 |
| Other Short Term Investments | $464,000,000 | $513,000,000 | $816,000,000 | $130,000,000 |
| Other Inventories | - | - | - | $-484,000,000 |
| Finished Goods | - | - | - | $509,000,000 |
| Work In Process | - | - | - | $1,850,000,000 |
| Raw Materials | - | - | - | $464,000,000 |
Fetched: 2026-05-23
Cash Flow Statement (Annual)
| Metric | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
| Free Cash Flow | ||||
| Free Cash Flow | $12,845,000,000 | $13,942,000,000 | $12,651,000,000 | $11,948,000,000 |
| Operating Activities | ||||
| Operating Cash Flow | $14,156,000,000 | $15,190,000,000 | $13,860,000,000 | $13,066,000,000 |
| Cash Flow From Continuing Operating Activities | $14,156,000,000 | $15,190,000,000 | $13,860,000,000 | $13,066,000,000 |
| Operating Gains Losses | $-1,445,000,000 | $-1,135,000,000 | $-724,000,000 | $-262,000,000 |
| Investing Activities | ||||
| Capital Expenditure | $-1,311,000,000 | $-1,248,000,000 | $-1,209,000,000 | $-1,118,000,000 |
| Investing Cash Flow | $-4,132,000,000 | $-21,352,000,000 | $-2,295,000,000 | $-1,062,000,000 |
| Cash Flow From Continuing Investing Activities | $-4,132,000,000 | $-21,352,000,000 | $-2,295,000,000 | $-1,062,000,000 |
| Capital Expenditure Reported | $-1,311,000,000 | $-1,248,000,000 | $-1,209,000,000 | $-1,118,000,000 |
| Financing Activities | ||||
| Repurchase Of Capital Stock | $0 | $0 | $-5,155,000,000 | $-8,001,000,000 |
| Financing Cash Flow | $-10,348,000,000 | $5,127,000,000 | $-9,416,000,000 | $-16,962,000,000 |
| Cash Flow From Continuing Financing Activities | $-10,348,000,000 | $5,127,000,000 | $-9,416,000,000 | $-16,962,000,000 |
| Cash Dividends Paid | $-5,045,000,000 | $-4,863,000,000 | $-4,744,000,000 | $-4,634,000,000 |
| Common Stock Dividend Paid | $-5,045,000,000 | $-4,863,000,000 | $-4,744,000,000 | $-4,634,000,000 |
| Net Common Stock Issuance | $0 | $0 | $-5,155,000,000 | $-8,001,000,000 |
| Net Other Financing Charges | - | - | - | - |
| Other | ||||
| Repayment Of Debt | $-10,940,000,000 | $-5,873,000,000 | $-3,999,000,000 | $-11,431,000,000 |
| Issuance Of Debt | $5,765,000,000 | $15,969,000,000 | $4,455,000,000 | $6,120,000,000 |
| End Cash Position | $10,218,000,000 | $10,347,000,000 | $11,519,000,000 | $9,325,000,000 |
| Beginning Cash Position | $10,347,000,000 | $11,519,000,000 | $9,325,000,000 | $14,316,000,000 |
| Effect Of Exchange Rate Changes | $195,000,000 | $-137,000,000 | $45,000,000 | $-33,000,000 |
| Changes In Cash | $-324,000,000 | $-1,035,000,000 | $2,149,000,000 | $-4,958,000,000 |
| Proceeds From Stock Option Exercised | $-128,000,000 | $-106,000,000 | $27,000,000 | $984,000,000 |
| Common Stock Payments | $0 | $0 | $-5,155,000,000 | $-8,001,000,000 |
| Net Issuance Payments Of Debt | $-5,175,000,000 | $10,096,000,000 | $456,000,000 | $-5,311,000,000 |
| Net Short Term Debt Issuance | $25,000,000 | $86,000,000 | $-120,000,000 | $194,000,000 |
| Short Term Debt Payments | $0 | $-3,000,000,000 | $-120,000,000 | $0 |
| Short Term Debt Issuance | $25,000,000 | $3,086,000,000 | $0 | $194,000,000 |
| Net Long Term Debt Issuance | $-5,200,000,000 | $10,010,000,000 | $576,000,000 | $-5,505,000,000 |
| Long Term Debt Payments | $-10,940,000,000 | $-2,873,000,000 | $-3,879,000,000 | $-11,431,000,000 |
| Long Term Debt Issuance | $5,740,000,000 | $12,883,000,000 | $4,455,000,000 | $5,926,000,000 |
| Net Investment Purchase And Sale | $52,000,000 | $618,000,000 | $-826,000,000 | $3,037,000,000 |
| Sale Of Investment | $2,052,000,000 | $1,387,000,000 | $948,000,000 | $6,629,000,000 |
| Purchase Of Investment | $-2,000,000,000 | $-769,000,000 | $-1,774,000,000 | $-3,592,000,000 |
| Net Business Purchase And Sale | $-2,873,000,000 | $-20,722,000,000 | $-260,000,000 | $-2,981,000,000 |
| Sale Of Business | $1,071,000,000 | $1,099,000,000 | $909,000,000 | $1,305,000,000 |
| Purchase Of Business | $-3,944,000,000 | $-21,821,000,000 | $-1,169,000,000 | $-4,286,000,000 |
| Change In Working Capital | $-455,000,000 | $810,000,000 | $-1,914,000,000 | $-2,229,000,000 |
| Change In Other Working Capital | $30,000,000 | $2,108,000,000 | $237,000,000 | $-183,000,000 |
| Change In Payables And Accrued Expense | $-6,000,000 | $-1,076,000,000 | $-405,000,000 | $-1,314,000,000 |
| Change In Payable | $-6,000,000 | $-1,076,000,000 | $-405,000,000 | $-1,314,000,000 |
| Change In Account Payable | $-2,000,000 | $184,000,000 | $198,000,000 | $109,000,000 |
| Change In Tax Payable | $-4,000,000 | $-1,260,000,000 | $-603,000,000 | $-1,423,000,000 |
| Change In Income Tax Payable | $-4,000,000 | $-1,260,000,000 | $-603,000,000 | $-1,423,000,000 |
| Change In Inventory | $-184,000,000 | $-486,000,000 | $-751,000,000 | $-69,000,000 |
| Change In Receivables | $-295,000,000 | $264,000,000 | $-995,000,000 | $-663,000,000 |
| Other Non Cash Items | $4,304,000,000 | $13,467,000,000 | $1,213,000,000 | $1,038,000,000 |
| Stock Based Compensation | $553,000,000 | $507,000,000 | $518,000,000 | $457,000,000 |
| Asset Impairment Charge | $1,098,000,000 | $2,963,000,000 | $255,000,000 | $179,000,000 |
| Deferred Tax | $-965,000,000 | $-2,089,000,000 | $-3,288,000,000 | $-2,738,000,000 |
| Deferred Income Tax | $-965,000,000 | $-2,089,000,000 | $-3,288,000,000 | $-2,738,000,000 |
| Depreciation Amortization Depletion | $4,011,000,000 | $9,600,000,000 | $9,760,000,000 | $10,276,000,000 |
| Depreciation And Amortization | $4,011,000,000 | $9,600,000,000 | $9,760,000,000 | $10,276,000,000 |
| Earnings Losses From Equity Investments | $-280,000,000 | $-16,000,000 | $160,000,000 | $801,000,000 |
| Gain Loss On Sale Of Business | $-1,165,000,000 | $-1,119,000,000 | $-884,000,000 | $-1,063,000,000 |
| Net Income From Continuing Operations | $7,055,000,000 | $-8,933,000,000 | $8,040,000,000 | $6,345,000,000 |
| Pension And Employee Benefit Expense | - | - | - | - |
Fetched: 2026-05-23